Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.
16/05/12
Angel signs new contract with ReNeuron15/05/12
Angel Biomedical Ltd announces supply agreement10/05/12
Acquisition of assets26/04/12
Holding(s) in Company17/04/12
Angel and TransGenRx Inc. sign contract15/05/12
Angel Biotechnology announces £400,000 collagen contract10/05/12
Angel Biotechnology sets up specialist collagen arm to focus on regenerative market17/04/12
Angel Biotechnologies secures contract from TransGenRx, shares rise06/02/12
Angel Biotechnology shares surge as it reveals new contracts worth total of £4.5mln22/12/11
Angel Biotechnology raises £1.15 million in cash call
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
